We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Read MoreHide Full Article
Key Takeaways
Spyre has a diversified pipeline spanning IBD, rheumatic diseases and hidradenitis suppurativa.
$1.15 billion in cash could fund operations into late 2029 and support several upcoming readouts.
Spyre faces elevated valuation, rising costs and competition as clinical results approach.
Spyre Therapeutics (SYRE - Free Report) has built a broad clinical-stage pipeline across inflammatory bowel disease, rheumatic diseases and hidradenitis suppurativa. Multiple proof-of-concept readouts could broaden the opportunity, while its cash balance gives the company time to advance several programs.
The trade-off is valuation and execution. SYRE has no marketed products or commercial revenues, while its shares have risen sharply. Additional clinical validation therefore remains important to the investment case.
Spyre Offers a Diversified Clinical Pipeline
Spyre’s core IBD strategy targets three validated pathways. SPY001 targets alpha 4 beta 7, SPY002 targets TL1A and SPY003 targets IL-23, with the candidates being tested as monotherapies and in pairwise combinations in the phase II SKYLINE study.
The approach already has clinical support. SPY002 produced 33% clinical remission and 42% endoscopic improvement at week 12 in ulcerative colitis. Beyond IBD, SPY072 is being studied across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, while SPY772 extends the pipeline into hidradenitis suppurativa.
SYRE's Cash Runway Supports Multiple Readouts
Spyre ended the second quarter of 2026 with $1.15 billion in cash, cash equivalents and marketable securities, up from $741.5 million at March 31. An April public offering added $435.2 million in net proceeds.
Management expects the current cash position to fund operations into the second half of 2029. That runway covers SPY003 data and rheumatology readouts in 2026, SKYLINE Part B induction data in 2027 and SKYLIGHT topline data expected in late 2027 or early 2028.
Spyre's Valuation Prices in Meaningful Success
The stock trades at 9.45X trailing 12-month book value per share, well above its five-year median of 2.71X. Shares have climbed 44.9% in the past three months and 512.7% in the past year.
That premium raises the stakes for future trial results. Spyre remains a development-stage biotechnology company without approved products, so its valuation is tied heavily to clinical success and the eventual commercial potential of its pipeline.
SYRE Faces High Development and Competition Risk
Research and development expenses rose 63.2% year over year to $65.5 million in the second quarter as manufacturing, clinical study and headcount costs increased. Spending is likely to remain elevated, creating longer-term financing and dilution risk despite the current runway.
AbbVie Inc. (ABBV - Free Report) raises the competitive bar with marketed IBD therapies SKYRIZI and RINVOQ across Crohn’s disease and ulcerative colitis. Johnson & Johnson (JNJ - Free Report) adds pressure through JNJ-4804, an investigational IL-23 and TNF co-antibody that advanced into phase 3 development after phase IIb testing in refractory IBD.
The current setup favors patience rather than chasing a stock that has already moved sharply. SYRE carries a Zacks Rank #3 (Hold), which can support maintaining an existing position but lacks the stronger fresh-buy signal associated with Zacks Rank #1 (Strong Buy) or #2 (Buy) stocks.
The Style Scores are mixed. SYRE has a Momentum Score of A, supporting the recent price trend, while its Value Score of F, Growth Score of F and VGM Score of F weaken the broader profile. With major clinical readouts ahead and valuation elevated, waiting remains reasonable. You can see the complete list of today’s Zacks #1 Rank stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Key Takeaways
Spyre Therapeutics (SYRE - Free Report) has built a broad clinical-stage pipeline across inflammatory bowel disease, rheumatic diseases and hidradenitis suppurativa. Multiple proof-of-concept readouts could broaden the opportunity, while its cash balance gives the company time to advance several programs.
The trade-off is valuation and execution. SYRE has no marketed products or commercial revenues, while its shares have risen sharply. Additional clinical validation therefore remains important to the investment case.
Spyre Offers a Diversified Clinical Pipeline
Spyre’s core IBD strategy targets three validated pathways. SPY001 targets alpha 4 beta 7, SPY002 targets TL1A and SPY003 targets IL-23, with the candidates being tested as monotherapies and in pairwise combinations in the phase II SKYLINE study.
The approach already has clinical support. SPY002 produced 33% clinical remission and 42% endoscopic improvement at week 12 in ulcerative colitis. Beyond IBD, SPY072 is being studied across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, while SPY772 extends the pipeline into hidradenitis suppurativa.
SYRE's Cash Runway Supports Multiple Readouts
Spyre ended the second quarter of 2026 with $1.15 billion in cash, cash equivalents and marketable securities, up from $741.5 million at March 31. An April public offering added $435.2 million in net proceeds.
Management expects the current cash position to fund operations into the second half of 2029. That runway covers SPY003 data and rheumatology readouts in 2026, SKYLINE Part B induction data in 2027 and SKYLIGHT topline data expected in late 2027 or early 2028.
Spyre's Valuation Prices in Meaningful Success
The stock trades at 9.45X trailing 12-month book value per share, well above its five-year median of 2.71X. Shares have climbed 44.9% in the past three months and 512.7% in the past year.
That premium raises the stakes for future trial results. Spyre remains a development-stage biotechnology company without approved products, so its valuation is tied heavily to clinical success and the eventual commercial potential of its pipeline.
SYRE Faces High Development and Competition Risk
Research and development expenses rose 63.2% year over year to $65.5 million in the second quarter as manufacturing, clinical study and headcount costs increased. Spending is likely to remain elevated, creating longer-term financing and dilution risk despite the current runway.
AbbVie Inc. (ABBV - Free Report) raises the competitive bar with marketed IBD therapies SKYRIZI and RINVOQ across Crohn’s disease and ulcerative colitis. Johnson & Johnson (JNJ - Free Report) adds pressure through JNJ-4804, an investigational IL-23 and TNF co-antibody that advanced into phase 3 development after phase IIb testing in refractory IBD.
Spyre Therapeutics, Inc. Price and Consensus
Spyre Therapeutics, Inc. price-consensus-chart | Spyre Therapeutics, Inc. Quote
SYRE's Scores Point to Patience Over Chasing
The current setup favors patience rather than chasing a stock that has already moved sharply. SYRE carries a Zacks Rank #3 (Hold), which can support maintaining an existing position but lacks the stronger fresh-buy signal associated with Zacks Rank #1 (Strong Buy) or #2 (Buy) stocks.
The Style Scores are mixed. SYRE has a Momentum Score of A, supporting the recent price trend, while its Value Score of F, Growth Score of F and VGM Score of F weaken the broader profile. With major clinical readouts ahead and valuation elevated, waiting remains reasonable. You can see the complete list of today’s Zacks #1 Rank stocks here.